Biohaven falls after depression drug fails mid-stage trial
24/12/2025 18:43
** Shares of drugmaker Biohaven BHVN.N fall 16% to $9 in extended trading ** Co says its drug, BHV-7000, did not meet the main goal of reduction of depressive symptoms in patients with major depressive disorder ** The drug was being studied in a proof-of-concept mid-stage study ** BHVN says it is not planning additional psychiatric clinical trials to keep resources focused on key priority areas of immunology, obesity and epilepsy in 2026 ** Up to last close, stock down 71% YTD (Reporting by Christy Santhosh) ((Christy.Santhosh@thomsonreuters.com))
Recent news on Biohaven
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
Brief: Biohaven - FDA Accepts Biohaven NDA Resubmission For Vyglxia (Troriluzole) In SCA
Biohaven jumps as FDA takes second look at brain disorder drug
Brief: Biohaven Enters Strategic Licensing Agreement With Ono Pharma
Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean